Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Theragen and GenVec combine stables

Theragen and GenVec combine stables One of the many dangers facing start-up companies is that the failure of one technology will leave the company with no fall-back position or that their technology base will prove to be too narrow to support a successful business. The search for a technology platform was the driving force behind the merger last week of two privately held gene therapy companies, Theragen Inc. and GenVec Inc.

The merger began as a hunt for a partnership, when Theragen decided that its herpes vector might have applications in the

Read the full 978 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers